143 studies found for:    folate receptor
Show Display Options
Rank Status Study
1 Unknown  The Development of Human Immunologic Assays Specific to Folate Receptor Antigen
Condition: Ovarian Cancer
Intervention: Procedure: venous puncture
2 Unknown  Measurement of the Folate Receptor in Blood
Condition: Healthy
3 Recruiting This First in Human Study of the New Therapeutic Antibody MOv18 IgE in Patients With Advanced Cancer
Condition: Human Cancers
Intervention: Drug: MOv18 IgE
4 Completed
Has Results
Does Valproate Increase Levels of Folate Receptor Autoantibodies in Women?
Conditions: Epilepsy;   Psychiatric or Mood Diseases or Conditions
Intervention: Other: No intervention
5 Recruiting Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer
Conditions: Adnexal Mass;   Borderline Ovarian Epithelial Tumor;   Ovarian Clear Cell Tumor;   Ovarian Endometrioid Tumor;   Ovarian Neoplasm;   Ovarian Serous Tumor;   Recurrent Ovarian Carcinoma
Interventions: Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis;   Drug: Valproic Acid
6 Recruiting Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
Condition: Breast Cancer
Interventions: Biological: Low dose FRα vaccine;   Drug: Cyclophosphamide;   Biological: High dose FRα vaccine
7 Unknown  FR in Stored Plasma
Condition: Ovarian Cancer
8 Completed Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma
Condition: Metastatic Renal Cell Carcinoma
Intervention: Drug: Technetium Tc 99m EC20
9 Recruiting Vaccine Therapy in Treating Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Following Surgery and Chemotherapy
Conditions: Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Tumor;   Fallopian Tube Mucinous Neoplasm;   Fallopian Tube Serous Neoplasm;   Fallopian Tube Transitional Cell Carcinoma;   Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
10 Active, not recruiting Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IIA Breast Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIB Breast Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Biological: Multi-epitope Folate Receptor Alpha Peptide Vaccine
11 Active, not recruiting Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: OTL38
12 Recruiting Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer
Conditions: Epithelial Ovarian Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer;   Endometrial Cancer
Interventions: Drug: IMGN853;   Drug: Bevacizumab;   Drug: Carboplatin;   Drug: Doxorubicin
13 Recruiting PH2 Study of IMGN853 vs Investigator's Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube Cancer
Conditions: Epithelial Ovarian Cancer;   Primary Peritoneal Carcinoma;   Primary Fallopian Tube Cancer
Interventions: Drug: IMGN853;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Gemcitabine;   Drug: Topotecan
14 Completed Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer
Condition: Non Small Cell Lung Cancer
Interventions: Drug: EC145;   Drug: EC145 + Docetaxel;   Drug: Docetaxel;   Drug: EC20
15 Completed A Study of MORAb-003 in Patients With Solid Tumor
Condition: Patients With a Folate-receptor Alpha Expressing Solid Tumor Who Are Not Responsive or Resistant to Standard Therapy and Have no Other Appropriate Treatment.
Intervention: Drug: MORAb-003
16 Terminated A Folinic Acid Intervention for Autism Spectrum Disorders
Conditions: Autism Spectrum Disorder;   Autistic Disorder;   Autism;   Asperger's Syndrome;   Pervasive Development Disorders
Interventions: Drug: Folinic Acid and placebo;   Drug: Folinic Acid
17 Completed Radiolabeled Folic Acid and Imaging to Detect Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Procedure: radionuclide imaging;   Radiation: indium In 111 folic acid
18 Recruiting Intraoperative Imaging of Pituitary Adenomas by OTL
Conditions: Neoplasms;   Pituitary Neoplasms
Intervention: Drug: OTL38
19 Recruiting Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly
Condition: Solid Tumours
Intervention: Drug: ONX-0801
20 Completed Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial Carcinoma
Conditions: Ovarian Carcinoma;   Recurrent Endometrial Carcinoma
Intervention: Drug: Tc 99m EC20

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years